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Abstract. In difference to other solid malignancies, the 
identification of biomarkers for the prediction of malignant 
melanoma (MM) response to immunotherapy is limited. The 
aim of the current study was to evaluate the immunohisto-
chemical (IHC) expression of MMR proteins in a cohort 
of MM metastatic patients receiving anti PD‑1 treatments. 
The therapeutic response of patients was also retrospec-
tively assessed. The cohort of the current study included 
14 patients with advanced MM that had received anti PD‑1 
from January 2014 to December 2016 (12 males, 2 females; 
average age, 71 years; age range, 47‑88 years). IHC analysis 
of MLH1, PMS2, MSH2 and MSH6 proteins was performed 
on paraffin‑embedded primary tumor samples from each 
patient and on the 23 available metastasis specimens obtained 
from the Division of Pathology (University of Modena and 
Reggio Emilia). The results revealed that 7% of the primary 
melanoma tissue obtained from the patient cohort exhibited 
the loss of expression of at least one MMR protein. Three 
samples from one patient, including one primary melanoma 
and two metastases, exhibited no MSH6 expression and had 
the most successful response to anti PD‑1 treatment, with a 
progression‑free survival and overall survival of 956 and 
2,546 days, respectively. In conclusion, the assessment of 
MMR protein expression represents a potential predictive 
marker that may have critical importance for patients with 
primary and metastatic MM, primarily as criterion for the 
adoption of immunotherapy treatments.
Introduction
At present, there is growing evidence suggesting that micro-
satellite instability (MSI) may be one possible predictive 
marker of immunotherapy response in many cancer types 
and in malignant melanoma (MM) (1‑7). The main cause of 
MSI is a defect in the DNA mismatch repair (MMR) genes, 
whose function is to repair the mismatched bases (8). Several 
repair genes (MSH2, MSH3, MSH6, MLH1, MLH3, PMS1 
and PMS2) are involved in this process and work by forming 
heterodimers. The interaction between mismatch recognition 
complexes and other proteins such as helicase, proliferating 
cell nuclear antigen, replication protein A, exonuclease 1 is 
required for the rectification of base‑pair alterations, inser-
tion‑deletion loops and hetero‑duplexes instigated during 
replication and recombination (9). MMR genes aberrations 
can be investigated by immunohistochemistry (IHC) for 
MMR proteins, which is a quick and simple assay to recog-
nize MMR status (10‑12).
There is a clear relationship between the loss of IHC 
expression of one or more MMR proteins and the MSI 
phenomenon (13,14). It was also known that the MSI status 
and the lack of MMR protein expression constitute a positive 
prognostic factor for colon cancer patients.
The reason of this evidence has been found in the enhanced 
immunogenicity of tumors characterized by MSI and MMR 
deficiency (MMR‑d), because their defective ability to repair 
DNA damages lead to a higher mutational burden and an 
increased generation of neoantigens (15).
The involvement of MMR genes was proposed in MM 
tumorigenesis (16). MSI was described in displastic naevi, 
MMs and MM metastases, suggesting that the MMR system 
and consequently MSI could contribute to the pathogenesis 
of MM (17). Differently to colon cancer and other solid 
malignancies that are treated with immunotherapy (1,18,19), 
potential IHC biomarkers are still limited for MM up to 
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now. This lack of predictive biomarkers for immunotherapy 
response in MM patients is today an important field of 
investigation, whose aim is to allow a personalized thera-
peutic approach. A targeted treatment in fact maximizes 
the patient's outcome, avoiding unnecessary risks for the 
patient's health and sparing important medical resources, 
because of the high costs of the new bioengineered drugs. 
The aim of our report was to evaluate the role of MMR 
IHC proteins expression as a predictive marker of immuno-
therapy response.
Patients and methods
The study was conducted in accordance with the World 
Medical Association Declaration of Helsinki regarding ethical 
conduct of research. The study was regularly approved on 
October 2014 by the ethics committee of the University of 
Modena and Reggio Emilia and written informed consent was 
provided by patients for IHC analysis. As a part of a systematic 
review of the medical record of patients affected by advanced 
MM receiving anti PD‑1 treatment from 2014 to 2016 at the 
Dermatology and Oncology Department of the University of 
Modena and Reggio Emilia, we collected the following data: 
Clinical stage of disease (AJCC 8th Ed., stage I‑IV) (20); 
primary tumor location; overall survival (OS), progression‑free 
survival (PFS) after anti PD‑1 therapy; adverse events during 
anti PD‑1 therapy. PFS was determined using the RECIST 
criteria (21).
IHC analysis of MSH6, MLH1, MSH2 and PMS2 
proteins were carried out on the paraffin‑embedded primary 
tumor samples of every included patients and on the 
available metastasis samples. The sections were cut (3‑4 µm) 
into superfrost plus microscope slides and allowed to dry 
at 37˚C overnight. The slides were submitted to antigen 
retrieval using microwave in 10 mmol/l citrate buffer, 
pH 6, at 350 W for 30 min. Immunoperoxidase staining, 
using diaminobenzidine as chromogen, was run with the 
NEX‑ES Automatic Staining System (Ventana). Monoclonal 
antibodies anti‑MSH6 (Clone 44; Transduction Laboratories; 
BD Biosciences) at 1:2,000, anti‑MLH1 (G168‑15) at 1:40, 
anti‑MSH2 (G129‑1129; both Pharmingen) at 1:40 dilution 
and anti PMS‑2 (Biocare Medical) at 1:40 dilution were used. 
Nuclei were counterstained with hematoxylin and adjacent 
normal tissue in each sample served as positive control. The 
complete absence of staining of tumor cells for one of the 
MMR proteins was considered indicative of a mismatch 
repair defect.
Results
We were able to identify 14 patients with advanced MM 
that were treated with anti PD‑1 during 2014‑2016 (Table I). 
Patients comprised 12 males and 2 females, average age was 
71 years, ranging from 47 to 88 years. MM was located on 
the head and neck area (n=2, 14%), on the trunk (n=7, 50%), 
on the upper limb (n=3, 22%, of which 2 were acral) and on 
the lower limb (n=2, 14%, of which 1 was acral); no patient 
of our series was affected by mucosal melanoma. The total 
number of metastases was 45: 10 were located at the lungs, 
8 at the lymph nodes, 6 at the skin, 3 in the retroperitoneum, 
3 at the bone, 3 at the spleen, 3 at the liver, 3 at the brain, 2 at 
the muscle, 1 at the gut, 1 at the stomach, 1 at the pancreas and 
1 at the kidney. Of these, only 23 were available as paraffin 
embedded samples.
Only three samples showed MMR‑d of MMR genes, 
in particular of MSH6: they were one primary subungual 
melanoma and two metastases (brain and ileus) belonging to 
the same female patient, whose complex clinical history is 
summarized by the time plot represented in Fig. 1. The IHC 
panels of the primary MM and related metastases of our 
MMR‑d and of an exemplificative MMR normal patient are 
shown in Figs. 2 and 3, respectively. Remarkably, she showed 
the best response to anti PD‑1 treatment of our cohort, with 
PFS and OS of 956 and 2,546 days, respectively. At present, 
the patient is still alive and in complete response. By contrast, 
MMR‑s patients showed average PFS and OS of 290 and 
542 days, respectively.
Discussion
The assessment of MMR protein expression represents a poten-
tial predictive marker which may have crucial importance for 
primary and metastatic MM patients. The identification of 
quick and simple assays to predict the response to anti PD‑1 
agents is one of the goal that the new era of MM immuno-
therapy should achieve in order to satisfy the compelling 
objectives of a personalized medicine.
Several studies have demonstrated that MMR gene 
deficiency is a more widespread phenomenon than first 
assumed, being present in many tumor types, such as 
colon cancer, ovarian cancer, brain tumors, biliary tract 
tumors and gastric cancer, but also in neuroblastoma and 
endometrial cancer (17). In a recent study by Kim et al (22) 
the MMR‑d tumor status was assessed in 430 consecutive 
solid tumors and was significantly correlated to the PD‑L1 
expression. Even though MMR‑d is a negative biomarker for 
MM chemotherapy sensitivity (23), recent evidences suggest 
that it may be a positive biomarker for immunotherapy 
response. In detail, it was demonstrated that MSI, which is 
often a consequence of MMR gene deficiency, is associated 
to a better response to immunotherapy in terms of PFS. As 
a general consideration, our hypothesis is that the presence 
of a mutator tumor phenotype allows an easier escape of the 
tumor to the pharmacokinetis of conventional chemotherapy, 
but, on the other hand, it produces many neoantigens that 
increase the immunogenicity of tumor cells. Thus, it is our 
hypothesis that the IHC analysis of MMR gene could be a 
marker that predict PFS and OS of MM patients treated by 
anti‑PD‑1 agents. In our population, the best PFS response 
was reached by the patient that showed MMR‑d tumor status, 
with lack of expression of MSH6, not associated to Lynch 
syndrome or Muir‑Torre Syndrome. The clinical history of 
the patient was complex and the previous treatment lead to 
unsatisfactory results. Noteworthy, anti PD‑1 therapy lead to 
a dramatic improvement of her management, with the regres-
sion of the brain and other metastasis, that are generally 
considered the prognostic factors that most negatively affect 
patient's survival. The limitations of our study consisted in 
the small population size and the lack of molecular biology 
investigations. Future studies are needed to investigate the 
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Figure 2. IHC of primary melanoma. When compared with MLH1, PMS2 and MSH2 levels, an exclusive loss of MSH6 expression was exhibited in a female 
case of subungual melanoma form the patient cohort, as determined via IHC. In the remaining cases of cutaneous melanoma, the expressions of MLH1, PMS2, 
MSH2 and MSH6 were within the normal range (scale bars, 100 µm). IHC, immunohistochemistry; MLH1, clone M1 Ventana; PMS2, clone EPR3947 Ventana; 
MSH2, clone G219‑1129; MSH6, clone 44 Ventana; H&E, hematoxylin and eosin.
Figure 1. Patient history. (A) Clinical history schematic of a representative patient who exhibited a loss of MSH6 expression in primary subungual melanoma 
tissue and in ileal and brain metastasis tissue. (B) CT scan of the patient's brain, presenting metastasis that was present prior to PD‑1 treatment. (C) Last CT 
scan of the patient, presenting regression of the metastasis (red arrow) after treatment with anti PD‑1. Green boxes represent the drugs administered, blue 
boxes represent follow‑up times and red boxes denote the associated clinical‑instrumental status. MSH6, clone 44 Ventana; PD‑1, programmed death ligand 1.
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role of MSI and MMR‑d during immunotherapy in animal 
model as well as in larger patient cohorts.
In conclusion, the assessment of MMR protein expression 
represents a potential predictive marker, which may have 
crucial importance for primary and metastatic MM patients, 
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